Effects of Quinoa Consumption on Markers of Cardiovascular Risk and Gastrointestinal Health
NCT ID: NCT03036618
Last Updated: 2017-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2016-08-31
2018-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quinoa Biscuit & CVD Risk Trial
NCT03291548
Effect of Barley Supplemented Wheat Bread on Markers of Cardiovascular and Renal Health
NCT05312788
Human Intervention Study for Validating Foods With Improved Nutrient Profile
NCT04113837
Effect of Amount and Type of Dietary Carbohydrates on Risk for Cardiovascular Heart Disease and Diabetes
NCT00608049
Meta-analysis of Oat Fiber and Cardiovascular Risk Reduction
NCT05171283
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
However, the effects of quinoa on humans has rarely been investigated with just two small interventions published. These studies also showed an improvement in blood lipid profile after consuming quinoa daily. There have been no studies which have investigated the effects of quinoa on gut bacteria and gastrointestinal health. Therefore, this human dietary intervention study aims to determine the effects of quinoa consumption on markers of cardiovascular diseases, the gut microbiome and gastrointestinal health.
The study is a randomized cross-over designed dietary intervention study with 4-week study periods separated by a 4-week wash-out period. The treatment will be the daily consumption of a test bread roll containing quinoa to deliver 20g quinoa per day (one roll per day). The control will be the same amount of a refined wheat roll. Markers of cardiovascular disease risk, including fasting blood lipid profile, plasma glucose and insulin concentration, resting blood pressure will be compared at the beginning and end of each treatment period. Changes in the numbers and species of gut bacteria, and products of bacterial fermentation will be made in stool samples collected at the beginning and end of each intervention period as indicators of gastrointestinal health.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Wheat
Test wheat bread roll (approximately 160g weight) without quinoa.
Wheat
Test wheat bread roll (approximately 160g weight) without quinoa.
Quinoa
Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
Quinoa
Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quinoa
Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
Wheat
Test wheat bread roll (approximately 160g weight) without quinoa.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. body mass index \>25 kg/m2
3. Non-smokers with no known previous history of cardiovascular disease or type 2 diabetes
4. Not receiving any current medication. Supplement users will be included but will be asked to stop taking supplements for the duration of the study
Exclusion Criteria
2. Smokers
3. Individuals with known or suspected allergy to wheat
4. Individuals with known history of cardiovascular diseases or type 2 diabetes
5. Individuals with recent weight loss (\>10%) or planning to lose weight during the study
35 Years
70 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Newcastle University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chris Seal, Professor
Role: PRINCIPAL_INVESTIGATOR
Newcastle University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NU-Food Research Facility
Newcastle upon Tyne, Tyne and Wear, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NUHEALTH-LL01-Quinoa
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.